Does Rallies track congressional trades in GMAB?

Yes. Rallies tracks politician and congressional stock disclosures for GMAB, including reported purchases, sales, dates, owners, and trade amounts when available.

Is GMAB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GMAB. It does not provide personalized investment advice.

GMAB (Genmab A/S ADS) Stock Analysis - Politician Trades

Genmab A/S ADS (GMAB) is a publicly traded Healthcare sector company. As of May 21, 2026, GMAB trades at $26.90 with a market cap of $16.19B and a P/E ratio of 0.00. GMAB moved +6.00% today. Year to date, GMAB is -14.43%; over the trailing twelve months it is +33.84%. Its 52-week range spans $17.24 to $35.43. Analyst consensus is strong buy with an average price target of $36.69. Rallies surfaces GMAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded GMAB stock?

Recent politician trading activity in GMAB includes disclosures from Josh Gottheimer, Josh Gottheimer, Josh Gottheimer, Josh Gottheimer, and Thomas R. Carper. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

GMAB Key Metrics

Key financial metrics for GMAB
Metric	Value
Price	$26.90
Market Cap	$16.19B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$35.43
52-Week Low	$17.24
Volume	10.42K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Congressional Trades in GMAB

Josh Gottheimer purchase GMAB on Jan 16, 2025 (amount: $15.00K) for Joint.
Josh Gottheimer sale GMAB on Dec 16, 2024 (amount: $15.00K) for Joint.
Josh Gottheimer purchase GMAB on Jul 19, 2024 (amount: $15.00K) for Joint.
Josh Gottheimer sale GMAB on Jun 18, 2024 (amount: $15.00K) for Joint.
Thomas R. Carper purchase GMAB on Nov 20, 2020 (amount: $15.00K) for Spouse.

Latest GMAB News

Genmab slides after Q1 2026 report shows higher costs despite 25% revenue growth — May 7, 2026
Genmab Cuts 2026 Revenue Estimate to $4.31B, Eyes 43% Upside — May 6, 2026
Genmab ADS slides as share cancellation and capital actions refocus sentiment — Apr 29, 2026
Genmab shares fall as investors reassess DARZALEX royalty outlook and capital actions — Apr 23, 2026
Genmab ADS jumps as Goldman upgrades to Buy on pipeline confidence — Apr 22, 2026

GMAB Analyst Consensus

9 analysts cover GMAB: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.69.

Common questions about GMAB

Which politicians traded GMAB stock?: Recent politician trading activity in GMAB includes disclosures from Josh Gottheimer, Josh Gottheimer, Josh Gottheimer, Josh Gottheimer, and Thomas R. Carper. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in GMAB?: Yes. Rallies tracks politician and congressional stock disclosures for GMAB, including reported purchases, sales, dates, owners, and trade amounts when available.
Is GMAB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GMAB. It does not provide personalized investment advice.